Effect of SARS-CoV-2 infection on outcome of cancer patients: A systematic review and meta-analysis of studies of unvaccinated patients

Abstract

AbstractBackgroundSince the beginning of the SARS-Cov-2 pandemic, cancer patients affected by COVID-19 have been reported to experience poor prognosis; however, a detailed quantification of the effect of SARS-CoV-2 infection on outcome of unvaccinated cancer patients has not been performed.MethodsTo carry out a systematic review of the studies on outcome of unvaccinated cancer patients infected by Sars-Cov-2, a search string was devised which was used to identify relevant publications in PubMed up to December 31, 2020. We selected three outcomes: mortality, access to ICU, and COVID-19 severity or hospitalization. We considered results for all cancers combined as well as for specific cancers. We conducted random-effects meta-analyses of the results, overall and after stratification by region. We also performed sensitivity analyses according to quality score and assessed publication bias.ResultsFor all cancer combined, the pooled odds ratio (OR) for mortality was 2.32 (95% confidence interval [CI] 1.82-2.94, I2 for heterogeneity 90.1%, 24 studies), that for ICU admission was 2.39 (95% CI 1.90-3.02, I2 0.0%, 5 studies), that for disease severity or hospitalization was 2.08 (95% CI 1.60-2.72, I2 92.1%, 15 studies). The pooled mortality OR for hematologic neoplasms was 2.14 (95% CI 1.87-2.44, I2 20.8%, 8 studies). Data were insufficient to perform a meta-analysis for other cancers. In the mortality meta-analysis for all cancers, the pooled OR was higher for studies conducted in Asia than studies conducted in Europe or North America. There was no evidence of publication bias.ConclusionsOur meta-analysis indicate a two-fold increased risk of adverse outcomes (mortality, ICU admission and severity of COVID-19) in unvaccinated cancer patients infected with SARS-CoV-2 compared to uninfected patients. These results should be compared with studies conducted in vaccinated patients; nonetheless, they argue for special effort to prevent SARS-CoV-2 infection in patients with cancer.FundingNo external funding was obtained.